DBV Technologies Yönetim

Yönetim kriter kontrolleri 3/4

DBV Technologies CEO'su Daniel Tassé, Nov2018 tarihinde atandı, in görev süresi 5.67 yıldır. in toplam yıllık tazminatı $ 2.40M olup, şirket hissesi ve opsiyonları dahil olmak üzere 25% maaş ve 75% ikramiyelerden oluşmaktadır. şirketin hisselerinin 0.018% ine doğrudan sahiptir ve bu hisseler € 10.60K değerindedir. Yönetim ekibinin ve yönetim kurulunun ortalama görev süresi sırasıyla 5.2 yıl ve 5.7 yıldır.

Anahtar bilgiler

Daniel Tassé

İcra Kurulu Başkanı

US$2.4m

Toplam tazminat

CEO maaş yüzdesi	25.0%
CEO görev süresi	6yrs
CEO sahipliği	0.02%
Yönetim ortalama görev süresi	5.2yrs
Yönetim Kurulu ortalama görev süresi	5.7yrs

Son yönetim güncellemeleri

Recent updates

CEO Tazminat Analizi

Daniel Tassé'un ücretlendirmesi DBV Technologies'un kazancına kıyasla nasıl değişti?
Tarih	Toplam Tazminat	Maaş	Şirket Kazançları
Sep 30 2024	n/a	n/a	-US$102m
Jun 30 2024	n/a	n/a	-US$88m
Mar 31 2024	n/a	n/a	-US$80m
Dec 31 2023	US$2m	US$600k	-US$73m
Sep 30 2023	n/a	n/a	-US$101m
Jun 30 2023	n/a	n/a	-US$101m
Mar 31 2023	n/a	n/a	-US$100m
Dec 31 2022	US$3m	US$600k	-US$96m
Sep 30 2022	n/a	n/a	-US$71m
Jun 30 2022	n/a	n/a	-US$77m
Mar 31 2022	n/a	n/a	-US$85m
Dec 31 2021	US$2m	US$600k	-US$98m
Sep 30 2021	n/a	n/a	-US$124m
Jun 30 2021	n/a	n/a	-US$131m
Mar 31 2021	n/a	n/a	-US$148m
Dec 31 2020	US$2m	US$600k	-US$160m
Sep 30 2020	n/a	n/a	-US$161m
Jun 30 2020	n/a	n/a	-US$171m
Mar 31 2020	n/a	n/a	-US$169m
Dec 31 2019	US$3m	US$600k	-US$172m
Sep 30 2019	n/a	n/a	-US$176m
Jun 30 2019	n/a	n/a	-US$198m
Mar 31 2019	n/a	n/a	-US$191m
Dec 31 2018	US$5m	US$55k	-US$190m

Tazminat ve Piyasa: Daniel 'nin toplam tazminatı ($USD 2.40M ), UK pazarındaki benzer büyüklükteki şirketler için ortalamanın üzerindedir ($USD 359.47K ).

Tazminat ve Kazançlar: Daniel 'in tazminatı, şirketin son bir yıldaki performansıyla tutarlıydı.

CEO

Daniel Tassé (64 yo)

6yrs

Görev süresi

US$2,404,486

Tazminat

Mr. Daniel Tasse had been an Independent Non-Executive Director of Indivior PLC since August 2014 until May 6, 2021 and Senior Independent Director since September 30, 2016 until May 6, 2021. Mr. Tasse ser...

Liderlik Ekibi

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Daniel Tassé	CEO & Director	6yrs	US$2.40m	0.018% € 11.2k
Virginie Simone Jeanine Boucinha	CFO & Principal Accounting Officer	less than a year	US$509.31k	0.0049% € 3.1k
Pharis Mohideen	Chief Medical Officer	5.3yrs	US$1.28m	0.024% € 15.2k
Kevin Malobisky	Chief Operations Officer	less than a year	Veri yok	Veri yok
Katie Matthews	Investor Relations Officer	no data	Veri yok	Veri yok
Michele Robertson	Chief Legal Officer	3.8yrs	Veri yok	Veri yok
Caroline Daniere	Chief Human Resources Officer & Chief of Staff	5.2yrs	Veri yok	Veri yok
Wence Agbotounou	Chief Clinical Trial Officer & Senior VP	8.5yrs	Veri yok	Veri yok
Edward Jordan	Senior Vice President of Commercial Operations North America	8.8yrs	Veri yok	Veri yok
Alan Kerr	Senior VP & Head of Global Regulatory Affairs	5.8yrs	Veri yok	Veri yok
Pascal Wotling	Chief External Manufacturing & Supply Chain Officer	less than a year	Veri yok	Veri yok
Robert Pietrusko	Chief Regulatory Officer	less than a year	Veri yok	Veri yok

5.2yrs

Ortalama Görev Süresi

57.5yo

Ortalama Yaş

Deneyimli Yönetim: 0QAJ 'un yönetim ekibi deneyimli ve deneyimlidir ( 5.2 yıldır).

Yönetim Kurulu Üyeleri

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Daniel Tassé	CEO & Director	5.7yrs	US$2.40m	0.018% € 11.2k
Timothy Morris	Independent Director	3.7yrs	US$113.54k	0.012% € 7.9k
Michel de Rosen	Independent Chairman of the Board	6.5yrs	US$10.81k	0.024% € 15.4k
Michael Goller	Director	9.1yrs	US$113.54k	0% € 0
Daniel Soland	Independent Director	9.7yrs	US$113.54k	0.026% € 16.4k
Mailys Ferrere	Director	8.4yrs	Veri yok	Veri yok
Hugh Sampson	Scientific Adviser to the CEO & Chairman of Scientific Advisory Board	3.9yrs	Veri yok	Veri yok
Paul-Henri Lambert	Member of the Scientific Advisory Board	no data	Veri yok	Veri yok
Emma Guttman-Yassky	Member of Scientific Advisory Board	5.5yrs	Veri yok	Veri yok
Julie O'Neill	Director	7.4yrs	US$113.54k	0% € 0
Jean-François Nicolas	Member of Scientific Advisory Board	5.5yrs	Veri yok	Veri yok
Jim Krueger	Member of Scientific Advisory Board	5.5yrs	Veri yok	Veri yok

5.7yrs

Ortalama Görev Süresi

64yo

Ortalama Yaş

Deneyimli Yönetim Kurulu: 0QAJ 'nin yönetim kurulu üyeleri deneyimli olarak kabul edilir (ortalama görev süresi 5.7 yıldır).

DBV Technologies Yönetim

Yönetim kriter kontrolleri 3/4

Anahtar bilgiler

Son yönetim güncellemeleri

Insufficient new directors

DBV Technologies S.A., Annual General Meeting, May 16, 2024

DBV Technologies S.A. Announces Executive Changes

DBV Technologies S.A. Announces Executive Changes

DBV Technologies S.A. Announces Executive Changes

High number of new directors

Recent updates

DBV Technologies Announces Plan to Implement ADS Ratio Change to Regain Compliance

Third quarter 2024 earnings released: US$0.32 loss per share (vs US$0.17 loss in 3Q 2023)

New major risk - Revenue and earnings growth

Dbv Technologies Announces Positive Regulatory Updates for the Viaskin Peanut Patch in the United States and Europe

Second quarter 2024 earnings released: US$0.34 loss per share (vs US$0.26 loss in 2Q 2023)

DBV Technologies S.A. to Report Q2, 2024 Results on Jul 30, 2024

New minor risk - Share price stability

DBV Technologies Provides Non-Compliance Update Related to Nasdaq Listing Rule 5550(a)(2) & 5810(c)(3)(A)

New minor risk - Market cap size

First quarter 2024 earnings released: US$0.28 loss per share (vs US$0.22 loss in 1Q 2023)

New major risk - Revenue and earnings growth

No longer forecast to breakeven

Insufficient new directors

DBV Technologies S.A., Annual General Meeting, May 16, 2024

New minor risk - Profitability

No longer forecast to breakeven

Full year 2023 earnings released: US$0.77 loss per share (vs US$1.24 loss in FY 2022)

New major risk - Financial position

DBV Technologies S.A. to Report Fiscal Year 2023 Results on Mar 07, 2024

New minor risk - Share price stability

Forecast to breakeven in 2026

DBV Technologies Receives a Letter from the Listing Qualifications Staff of the Nasdaq Stock Market

DBV Technologies S.A. to Present New Data at ACAAI 2023

Third quarter 2023 earnings released: US$0.17 loss per share (vs US$0.18 loss in 3Q 2022)

DBV Technologies S.A. to Report Q3, 2023 Results on Oct 31, 2023

DBV Technologies S.A. Announces Executive Changes

DBV Technologies S.A. Announces Executive Changes

Dbv Technologies S.A. Receives Feedback from FDA on Design Elements for Viaskin Peanut Safety Studies

Second quarter 2023 earnings released: US$0.26 loss per share (vs US$0.35 loss in 2Q 2022)

DBV Technologies S.A. to Report First Half, 2023 Results on Jul 31, 2023

New minor risk - Shareholder dilution

First quarter 2023 earnings released: US$0.22 loss per share (vs US$0.30 loss in 1Q 2022)

Full year 2022 earnings released: US$1.24 loss per share (vs US$1.78 loss in FY 2021)

Forecast to breakeven in 2025

DBV Technologies Announces FDA Lifts Partial Clinical Hold on VITESSE Phase 3 Pivotal Trial

Third quarter 2022 earnings released: US$0.18 loss per share (vs US$0.44 loss in 3Q 2021)

DBV Technologies S.A. Announces Executive Changes

DBV Technologies S.A. Receives Feedback from the U.S. Food and Drug Administration in the Form of a Partial Clinical Hold on Its VITESSE Phase 3 Clinical Study

DBV Technologies S.A. Announces Initiation of Phase 3 Study (VITESSE) Using the Modified Viaskin Peanut Patch in Peanut -Allergic Children Ages 4 to 7 Years

Second quarter 2022 earnings released: US$0.35 loss per share (vs US$0.56 loss in 2Q 2021)

DBV Technologies S.A. announced that it has received €82.00136 million in funding from Vivo Capital, LLC, RA Capital Management, L.P., VR Adviser, LLC, Baker Bros. Advisors LP, Braidwell LP, Fairmount Funds Management LLC

DBV Technologies S.A. announced that it expects to receive €82.00136 million in funding from Vivo Capital, LLC, RA Capital Management, L.P., VR Adviser, LLC, Baker Bros. Advisors LP, Braidwell LP, and other investor

DBV Technologies S.A. announced that it expects to receive €82.00136 million in funding from Vivo Capital, LLC, RA Capital Management, L.P., VR Adviser, LLC, Baker Bros. Advisors LP, Braidwell LP, and other investor

DBV Technologies Announces Positive Topline Results from Phase 3 Epitope Trial of Viaskin Peanut in Peanut-Allergic Toddlers

First quarter 2022 earnings released: US$0.30 loss per share (vs US$0.54 loss in 1Q 2021)

High number of new directors

Full year 2021 earnings: EPS in line with analyst expectations despite revenue beat

No longer forecast to breakeven

DBV Technologies S.A. to Report Q1, 2022 Results on May 02, 2022

DBV Technologies S.A. Provides Update on Investigational Viaskin Peanut

Third quarter 2021 earnings released: US$0.44 loss per share (vs US$0.56 loss in 3Q 2020)

Second quarter 2021 earnings released: US$0.56 loss per share (vs US$0.88 loss in 2Q 2020)

Independent Director has left the company

First quarter 2021 earnings released: US$0.54 loss per share (vs US$0.89 loss in 1Q 2020)

Revenue misses expectations

DBV Technologies Announces Appointment of Michele F. Robertson as Chief Legal Officer

DBV Technologies S.A. to Report First Half, 2021 Results on Aug 02, 2021

DBV Technologies Provides Update on Investigational Viaskin™ Peanut for Children Ages 4-11 Years

New 90-day high: €5.58

New 90-day high: €4.41

Hugh Sampson Decides to Step Down as Chief Scientific Officer of DBV Technologies, Effective December 1, 2020

New 90-day high: €4.21

DBV Technologies to Highlight Data on Viaskin™ Peanut Treatment Delivery and Patient Experience at ACAAI 2020

DBV Technologies S.A. Announces Filing and Validation of Marketing Authorization Application for Viaskin™ Peanut by European Medicines Agency

New 90-day low: €2.79

New 90-day low: €3.37

New 90-day low - €3.71

New 90-day low - €4.13

CEO Tazminat Analizi